Articles related to RESEARCH & CLINICAL TRIALS

In cisplatin-eligible patients with muscle-invasive bladder cancer, perioperative durvalumab combined with standard chemotherapy demonstrated an 8% absolute improvement in event-free survival at 24 months compared to chemotherapy alone.

In this multicenter trial of 901 patients with asymptomatic severe aortic stenosis, early TAVR intervention reduced the composite endpoint of death, stroke, or unplanned cardiovascular hospitalization by 50% compared to clinical surveillance.

In patients with heart failure and preserved ejection fraction, finerenone demonstrated a 16% reduction in the primary composite endpoint of total worsening heart failure events and cardiovascular death compared to placebo.

Luspatercept demonstrates superior efficacy in achieving transfusion independence for patients with low-risk MDS compared to traditional erythropoiesis-stimulating agents.

A recent phase 3 trial comparing nivolumab plus AVD to brentuximab vedotin plus AVD in advanced-stage Hodgkin’s lymphoma demonstrated a significant improvement in 2-year progression-free survival (92% vs. 83%, respectively) with a hazard ratio for disease progression or death of 0.45 (95% CI, 0.30 to 0.65).

The inavolisib-based regimen more than doubled progression-free survival in PIK3CA-mutated breast cancers, offering a new standard of care for this challenging patient population.